Wall Street analysts expect ADMA Biologics Inc (NASDAQ:ADMA) to post $5.56 million in sales for the current quarter, Zacks reports. Four analysts have made estimates for ADMA Biologics’ earnings. The lowest sales estimate is $4.70 million and the highest is $6.00 million. ADMA Biologics reported sales of $12.00 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 53.7%. The company is expected to issue its next quarterly earnings report on Monday, March 4th.

According to Zacks, analysts expect that ADMA Biologics will report full-year sales of $18.38 million for the current financial year, with estimates ranging from $17.70 million to $18.90 million. For the next financial year, analysts anticipate that the business will report sales of $44.40 million, with estimates ranging from $19.90 million to $94.20 million. Zacks’ sales averages are an average based on a survey of analysts that follow ADMA Biologics.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Thursday, November 8th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.02). ADMA Biologics had a negative return on equity of 155.19% and a negative net margin of 243.42%. The business had revenue of $4.23 million for the quarter, compared to analysts’ expectations of $5.39 million.

ADMA has been the subject of several research analyst reports. Oppenheimer set a $13.00 price objective on ADMA Biologics and gave the company a “buy” rating in a research note on Monday, November 12th. HC Wainwright set a $17.00 price objective on ADMA Biologics and gave the company a “buy” rating in a research note on Friday, November 9th. Maxim Group reaffirmed a “buy” rating and issued a $12.00 price objective on shares of ADMA Biologics in a research note on Wednesday, October 17th. Finally, Raymond James reaffirmed a “buy” rating and issued a $10.00 price objective (down from $11.00) on shares of ADMA Biologics in a research note on Friday, October 12th. Six equities research analysts have rated the stock with a buy rating, ADMA Biologics has a consensus rating of “Buy” and an average target price of $11.58.

NASDAQ ADMA traded down $0.13 during mid-day trading on Friday, hitting $3.22. The stock had a trading volume of 700 shares, compared to its average volume of 321,650. ADMA Biologics has a 52-week low of $2.08 and a 52-week high of $6.96. The company has a market capitalization of $158.52 million, a P/E ratio of -1.69 and a beta of 2.84. The company has a debt-to-equity ratio of 1.11, a current ratio of 6.32 and a quick ratio of 4.92.

A number of institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc increased its position in ADMA Biologics by 5.2% during the third quarter. Vanguard Group Inc now owns 1,192,641 shares of the biotechnology company’s stock worth $7,406,000 after buying an additional 58,610 shares in the last quarter. Vanguard Group Inc. increased its position in ADMA Biologics by 5.2% during the third quarter. Vanguard Group Inc. now owns 1,192,641 shares of the biotechnology company’s stock worth $7,406,000 after buying an additional 58,610 shares in the last quarter. Renaissance Technologies LLC increased its position in ADMA Biologics by 544.9% during the third quarter. Renaissance Technologies LLC now owns 188,300 shares of the biotechnology company’s stock worth $1,169,000 after buying an additional 159,100 shares in the last quarter. JPMorgan Chase & Co. increased its position in ADMA Biologics by 54.7% during the third quarter. JPMorgan Chase & Co. now owns 228,999 shares of the biotechnology company’s stock worth $1,422,000 after buying an additional 81,003 shares in the last quarter. Finally, Northern Trust Corp increased its position in ADMA Biologics by 618.2% during the second quarter. Northern Trust Corp now owns 209,313 shares of the biotechnology company’s stock worth $944,000 after buying an additional 180,170 shares in the last quarter. 57.49% of the stock is owned by institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Recommended Story: How Important is Technical Analysis of Stocks

Get a free copy of the Zacks research report on ADMA Biologics (ADMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.